obesity drug news today glp-1 october 27 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford October 27, 2025: U.K. regulators

doi:10.3748/wjg.v26.i21.2740 23

Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter, double-blind, placebo-controlled Phase 3 trials with safety-extension data

Bioactive peptides, such as antimicrobial peptides, exhibit strong activity against a variety of pathogens, including bacteria, viruses, and fungi, making them invaluable in combating infections

notably, close to 50% of these deals were signed for drug development and commercialization

This is why many people choose peptides as a natural and targeted way to improve their health and feel their best

(2025, Nature Metabolism ) reported daLUXendin and daLUXendin+, non-lipidated and lipidated dual GLP-1/GIP receptor agonist fluorescent probes with nanomolar affinity at both hGLP1R and hGIPR